Avenue Therapeutics (ATXI)
(Delayed Data from NSDQ)
$2.54 USD
+0.02 (0.79%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.54 USD
+0.02 (0.79%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Avenue Therapeutics, Inc. (ATXI) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.40, moving -1.61% from the previous trading session.
Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $9.83, moving -0.91% from the previous trading session.
Revolution Medicines (RVMD) Catches Eye: Stock Jumps 10.2%
by Zacks Equity Research
Revolution Medicines (RVMD) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $9.75, moving -1.52% from the previous trading session.
Is Avenue Therapeutics (ATXI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ATXI) Outperforming Other Medical Stocks This Year?
Pacira (PCRX) Provides Preliminary Results for Second Quarter
by Zacks Equity Research
Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic. The stock fell in pre-market trading.
Zynerba's Zygel Fails in Phase III Fragile X Syndrome Study
by Zacks Equity Research
Zynerba's (ZYNE) shares plunge 48.5% following the study data readout, which demonstrated failure to achieve statistical significance in primary endpoint.
Alpine Begins Dosing in Phase I Study for Advanced Malignancies
by Zacks Equity Research
Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.
Veru (VERU) Soars: Stock Adds 6.9% in Session
by Zacks Equity Research
Veru (VERU) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Avenue Therapeutics, Inc. (ATXI) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Applied Genetic (AGTC) Soars: Stock Adds 6.1% in Session
by Zacks Equity Research
Applied Genetic (AGTC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
New Strong Buy Stocks for June 24th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Avenue Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Avenue Therapeutics
Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study
by Zacks Equity Research
Aclaris (ACRS) announces that it supports an IND application to evaluate its oral investigational MK2 inhibitor compound, ATI-450, in hospitalized patients with COVID-19.
NGM Biopharmaceuticals (NGM) Soars: Stock Adds 7.8% in Session
by Zacks Equity Research
NGM Biopharmaceuticals (NGM) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Is Avenue Therapeutics (ATXI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ATXI) Outperforming Other Medical Stocks This Year?
Provention Bio (PRVB) Looks Good: Stock Adds 8.6% in Session
by Zacks Equity Research
Provention Bio (PRVB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Zacks.com featured highlights include: Frontline, iClick Interactive Asia, Avenue Therapeutics, ProQR Therapeutics and BJ???s Wholesale Club
by Zacks Equity Research
Zacks.com featured highlights include: Frontline, iClick Interactive Asia, Avenue Therapeutics, ProQR Therapeutics and BJ???s Wholesale Club
Soleno (SLNO) Looks Good: Stock Adds 6.8% in Session
by Zacks Equity Research
Soleno (SLNO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
5 Low-Beta Stocks to Beat Renewed Coronavirus Concerns
by Nilanjan Banerjee
To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.
NantHealth (NH) Looks Good: Stock Adds 9.1% in Session
by Zacks Equity Research
NantHealth (NH) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Otonomy (OTIC) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
Otonomy (OTIC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Infinity (INFI) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
Infinity (INFI) saw a big move last session, as its shares jumped nearly 5% on the day, amid huge volumes.
Recro Pharma (REPH) in Focus: Stock Moves 7.6% Higher
by Zacks Equity Research
Recro Pharma (REPH) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Zacks.com featured highlights include: Avenue Therapeutics, Calix, ChannelAdvisor and Magic Software Enterprises
by Zacks Equity Research
Zacks.com featured highlights include: Avenue Therapeutics, Calix, ChannelAdvisor and Magic Software Enterprises